Estimating the overall survival benefit of adjuvant chemo-endocrine therapy in women over age 50 with pT1-2N0 early stage breast cancer and 21-gene recurrence score ≥26: A National Cancer Database analysis.
Nickolas StabelliniLifen CaoChristopher W ToweAmanda L AminAlberto J MonteroPublished in: Cancer medicine (2023)
We observed that CET was associated with a clinically and statistically significant higher OS compared to ET alone in women >50 years of age with RS ≥26 pT1 and pT2 N0M0 HR+/HER2-breast cancer, and which suggests that cytotoxic chemotherapy has an impact on reducing mortality that is independent of induction of premature ovarian failure.
Keyphrases
- early stage
- breast cancer risk
- polycystic ovary syndrome
- pregnancy outcomes
- free survival
- locally advanced
- cervical cancer screening
- cardiovascular events
- sentinel lymph node
- risk factors
- insulin resistance
- squamous cell carcinoma
- cancer therapy
- adipose tissue
- type diabetes
- dna methylation
- coronary artery disease
- metabolic syndrome
- young adults
- gene expression
- transcription factor
- combination therapy
- electronic health record
- cell therapy
- genome wide identification